Wollenberg A, Silverberg JI, Legat FJ, Tauber M, et al. Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic Dermatitis. Acta Derm Venereol 2026;106:0085.
PMID: 42272192